Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

  1. Home
  2. /Competitive
  3. /Landscape Reports

Competitive

Landscape Reports(4)

Monitor how competitors respond to market openings, data releases, and regulatory milestones across key franchises.

4 signals

ScoreIntelligence Record
7.0

COMPETITIVE

Bruceine D shows potential to overcome EGFR-TKI resistance in lung adenocarcinoma

Bruceine D epigenetically restores SMAD3 expression and suppresses malignant progression in EGFR-TKI-resistant lung adenocarcinoma.

Bruceine·July 24, 2026
7.0

COMPETITIVE

CAR-T Cell Therapy for ALL: Emerging Research Trends and Focus Areas Identified

A bibliometric analysis reveals a significant growth in CAR-T cell therapy research for acute lymphoblastic leukemia, with a focus on long-term outcomes and risk assessment.

July 22, 2026
7.0

COMPETITIVE

Infrastructure Proposal for mHealth Interventions in Cancer Patient Smoking Cessation

A new infrastructure is being proposed to support the development of mobile health tools aimed at reducing smoking among cancer patients.

Infrastructure·July 18, 2026
8.0

COMPETITIVE

Novel CDK7 Inhibitor 7a Shows Potent Antitumor Activity in Colorectal Cancer Models

Compound 7a is a highly selective CDK7 inhibitor with an IC50 of 1.9 nM, demonstrating significant antitumor efficacy in HCT116 models.

Novel·July 14, 2026

Showing 1–4 of 4 records

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.